title: Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer.
abstract: BACKGROUND
  MicroRNAs are novel regulators of gene expression that are linked to the main oncogene networks, including the p53 pathway. p53 regulates the maturation process of miR-16 and miR-143. We analyzed the role as prognostic markers of miR-16 and miR-143 in 70 non-small-cell lung cancer (NSCLC) patients.
  
  
  METHODS
  MicroRNAs were analyzed by TaqMan MicroRNA assays. Disease-free survival (DFS) and overall survival (OS) were examined using Kaplan-Meier curves with log-rank tests and the Cox proportional hazard model.
  
  
  RESULTS
  When patients were classified in three groups according to their miR-16 expression levels, those with normal levels had the best outcome while those with high levels had the worst. DFS was 22.4 months for patients with high levels, 71.8 months for those with normal levels, and 55.8 months for those with low levels (P = 0.05). OS was 23.9 months for patients with high levels, 97.6 months for those with normal levels, and 63.5 months for those with low levels (P < 0.001). In the multivariate analyses, high miR-16 levels emerged as an independent prognostic factor for poor DFS (P = 0.001) and OS (<0.001).
  
  
  CONCLUSIONS
  Our results provide the first hints that miR-16 levels in tumor samples may be a prognostic marker in NSCLC.
authors.affiliation: Human Anatomy and Embryology Unit, Molecular Oncology and Embryology Laboratory, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain.
authors.forename: Alfons
authors.initials: A
authors.lastname: Navarro
authors.forename: Tania
authors.initials: T
authors.lastname: Diaz
authors.forename: Elena
authors.initials: E
authors.lastname: Gallardo
authors.forename: Nuria
authors.initials: N
authors.lastname: Viñolas
authors.forename: Ramon M
authors.initials: RM
authors.lastname: Marrades
authors.forename: Bernat
authors.initials: B
authors.lastname: Gel
authors.forename: Marc
authors.initials: M
authors.lastname: Campayo
authors.forename: Angels
authors.initials: A
authors.lastname: Quera
authors.forename: Eva
authors.initials: E
authors.lastname: Bandres
authors.forename: Jesus
authors.initials: J
authors.lastname: Garcia-Foncillas
authors.forename: Jose
authors.initials: J
authors.lastname: Ramirez
authors.forename: Mariano
authors.initials: M
authors.lastname: Monzo
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D009367:Neoplasm Staging; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D012189:Retrospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000235:genetics
chemical_list: C542359:MIRN143 microRNA, human; C505362:MIRN16 microRNA, human; D035683:MicroRNAs; D012333:RNA, Messenger; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53